Merck
  • Início
  • Resultados da busca
  • Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas.

Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas.

Blood (2011-05-06)
Marco Guadagnoli, Fiona C Kimberley, Uyen Phan, Katherine Cameron, Paul M Vink, Hans Rodermond, Eric Eldering, Arnon P Kater, Hans van Eenennaam, Jan Paul Medema
RESUMO

APRIL (A proliferation-inducing ligand) is a TNF family member that binds two TNF receptor family members, TACI and BCMA. It shares these receptors with the closely related TNF family member, B-cell activating factor (BAFF). Contrary to BAFF, APRIL binds heparan sulfate proteoglycans (HSPGs), which regulates cross-linking of APRIL and efficient signaling. APRIL was originally identified as a growth promoter of solid tumors, and more recent evidence defines APRIL also as an important survival factor in several human B-cell malignancies, such as chronic lymphocytic leukemia (CLL). To target APRIL therapeutically, we developed two anti-human APRIL antibodies (hAPRIL.01A and hAPRIL.03A) that block APRIL binding to BCMA and TACI. Their antagonistic properties are unique when compared with a series of commercially available monoclonal anti-human APRIL antibodies as they prevent in vitro proliferation and IgA production of APRIL-reactive B cells. In addition, they effectively impair the CLL-like phenotype of aging APRIL transgenic mice and, more importantly, block APRIL binding to human B-cell lymphomas and prevent the survival effect induced by APRIL. We therefore conclude that these antibodies have potential for further development as therapeutics to target APRIL-dependent survival in B-cell malignancies.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
SyntheChol® NS0 Supplement, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture